



June 3, 2019

Awny Farajallah, MD, FACP
Vice President, Head US Medical Oncology
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrence Township, NJ 08648
awny.farajallah@bms.com

NCCN Guidelines® Panel: Colon/Rectal/Anal Cancers

Dear Panel Members:

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed clinical data regarding the use of nivolumab in combination with ipilimumab for treatment of metastatic colorectal cancer that was recently presented as a poster presentation at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting, to the NCCN® Colon/Rectal/Anal Cancers panel. This data from the phase 2, open-label study, CheckMate 142, presented additional follow up on the use of nivolumab in combination with ipilimumab as a first-line treatment for patients with previously untreated deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC), and is being provided for the panel's consideration.¹

FDA Clearance of OPDIVO® (nivolumab) (indication in metastatic colorectal cancer):

- Adult and pediatric (12 years and older) patients with MSI-H or dMMR metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab.²

The use of nivolumab in combination with ipilimumab as a first-line treatment for dMMR/MSI-H mCRC is considered investigational.^{2,3}

Rationale: This data is being submitted in response to a standing request from NCCN for new clinical data. Primary disclosure of data on the use of nivolumab in combination with ipilimumab as a first-line treatment for patients with previously untreated dMMR/MSI-H mCRC was submitted to the NCCN on October 22, 2018. Data enclosed here reflects 19.9 months median follow up in the same cohort of patients.

The following resources are included for your review:

1. Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab + Low-Dose Ipilimumab as First-Line Therapy in Microsatellite Instability-High/DNA Mismatch Repair Deficient Metastatic Colorectal Cancer: Clinical Update. Poster presentation at the 2019 ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA.
2. Product information, OPDIVO® (nivolumab) injection, for intravenous infusion. Bristol-Myers Squibb Company, Princeton, NJ. May 2019.
3. Product information, YERVOY® (ipilimumab) injection, for intravenous infusion. Bristol-Myers Squibb Company, Princeton, NJ. May 2019.

Thank you for your consideration of this request.

Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical Oncology
Bristol-Myers Squibb Company
609-302-3927; awny.farajallah@bms.com